Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIN1 | Q05586 | 3/20 | 0.51 |
| ▸ | GRIN2A | Q12879 | 3/20 | 0.51 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.51 |
| ▸ | GRIN2D | O15399 | 2/20 | 0.51 |
| ▸ | GRIN3B | O60391 | 2/20 | 0.51 |
| ▸ | GRIN2B | Q13224 | 2/20 | 0.51 |
| ▸ | GRIN2C | Q14957 | 2/20 | 0.51 |
| ▸ | GRIN3A | Q8TCU5 | 2/20 | 0.51 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.51 |
| ▸ | LMNA | P02545 | 1/20 | 0.51 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.51 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.51 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21452130 | 0.80 | GRIN1 (0.36) | GRIN1GRIN2ASLC6A4GRIN2DGRIN3B | |
| SCHEMBL21452103 | 0.71 | HDAC4 (0.44) | GRIN1GRIN2ASLC6A4OPRK1LMNA | |
| Norketamine SCHEMBL30089862 | 0.70 | GRIN1 (0.59) | GRIN1GRIN2ASLC6A4GRIN2DGRIN3B | |
| Norketamine SCHEMBL12601748 | 0.70 | GRIN1 (0.59) | GRIN1GRIN2ASLC6A4GRIN2DGRIN3B | |
| Norketamine SCHEMBL30089863 | 0.70 | GRIN1 (0.59) | GRIN1GRIN2ASLC6A4GRIN2DGRIN3B | |
| SCHEMBL24305439 | 0.70 | GRIN1 (0.59) | GRIN1GRIN2ASLC6A4GRIN2DGRIN3B | |
| SCHEMBL3716669 | 0.70 | GRIN1 (0.59) | GRIN1GRIN2ASLC6A4GRIN2DGRIN3B | |
| Norketamine SCHEMBL3390132 | 0.70 | GRIN1 (0.59) | GRIN1GRIN2ASLC6A4GRIN2DGRIN3B | |
| SCHEMBL19992375 | 0.70 | GRIN1 (0.63) | GRIN1GRIN2ASLC6A4GRIN2DGRIN3B | |
| SCHEMBL31240478 | 0.70 | GRIN1 (0.59) | GRIN1GRIN2ASLC6A4GRIN2DGRIN3B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114716332-B | Preparation method of ketamine | 宜昌人福药业有限责任公司 | 2023-06-02 | — | — | CN | claimed |
| CN-114716332-A | Preparation method of ketamine | 宜昌人福药业有限责任公司 | 2022-07-08 | — | — | CN | claimed |
| CN-110818587-B | Preparation method of ketamine and synthesis method of intermediate compound | 宜昌人福药业有限责任公司 | 2022-06-03 | — | — | CN | claimed |
| CN-110818587-A | Preparation method of ketamine and synthesis method of intermediate compound | 宜昌人福药业有限责任公司 | 2020-02-21 | — | — | CN | claimed |
| US-20230312500-A1 | LONG-ACTING LOW-ADDICTION HNK DERIVATIVE AND PREPARATION METHOD THEREFOR | SHENZHEN RUIJIAN BIOTECHNOLOGY CO., LTD (CN) | 2023-10-05 | — | — | US | disclosed |
| US-20230312500-A1 | LONG-ACTING LOW-ADDICTION HNK DERIVATIVE AND PREPARATION METHOD THEREFOR | SHENZHEN RUIJIAN BIOTECHNOLOGY CO., LTD (CN) | 2023-10-05 | — | — | US | disclosed |
| US-20230303481-A1 | LONG-ACTING LOW-ADDICTION HNK DERIVATIVE AND PREPARATION METHOD THEREFOR | SHENZHEN RUIJIAN BIOTECHNOLOGY CO., LTD (CN) | 2023-09-28 | — | — | US | disclosed |
| CN-114716332-B | Preparation method of ketamine | 宜昌人福药业有限责任公司 | 2023-06-02 | — | — | CN | disclosed |
| CN-114716332-B | Preparation method of ketamine | 宜昌人福药业有限责任公司 | 2023-06-02 | — | — | CN | disclosed |
| CN-114716332-A | Preparation method of ketamine | 宜昌人福药业有限责任公司 | 2022-07-08 | — | — | CN | disclosed |
| CN-114716332-A | Preparation method of ketamine | 宜昌人福药业有限责任公司 | 2022-07-08 | — | — | CN | disclosed |
| CN-110818587-B | Preparation method of ketamine and synthesis method of intermediate compound | 宜昌人福药业有限责任公司 | 2022-06-03 | — | — | CN | disclosed |
| EP-3463323-B1 | SOLID ORAL DOSAGE FORMS OF 2R,6R-HYDROXYNORKETAMINE OR DERIVATIVES THEREOF | SMALL PHARMA LTD (GB) | 2021-10-20 | — | — | EP | disclosed |
| CN-110818587-A | Preparation method of ketamine and synthesis method of intermediate compound | 宜昌人福药业有限责任公司 | 2020-02-21 | — | — | CN | disclosed |
| WO-2017208031-A1 | SOLID ORAL DOSAGE FORMS OF 2R,6R-HYDROXYNORKETAMINE OR DERIVATIVES THEREOF | SMALL PHARMA LTD (GB) | 2017-12-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230312500-A1 | LONG-ACTING LOW-ADDICTION HNK DERIVATIVE AND PREPARATION METHOD THEREFOR | OPRK1, OPRL1, GRIK1 | GRIN1 15/4885GRIN2A 18/4885SLC6A4 116/4885 |
| US-20230303481-A1 | LONG-ACTING LOW-ADDICTION HNK DERIVATIVE AND PREPARATION METHOD THEREFOR | OPRK1, OPRL1, NTRK1 | GRIN1 11/4885GRIN2A 10/4885SLC6A4 128/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.